Skip to content

Establishment of a Six-Meridian Syndrome Differentiation Model-based Clinical Pathway for Community-Acquired Pneumonia in Traditional Chinese Medicine and Its Application Research

Establishment of a Six-Meridian Syndrome Differentiation Model-based Clinical Pathway for Community-Acquired Pneumonia in Traditional Chinese Medicine and Its Application Research

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000070
Enrollment
Unknown
Registered
2026-01-13
Start date
2024-07-23
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

community-acquired pneumonia

Interventions

Treatment group:The subjects in the treatment group will receive the standardized clinical pathway of the corresponding syndrome differentiation of the six meridians within one week after enrollment,
Control group:The control group in this study is a historical control group, and no concurrent parallel control group is established. The data of the control group is derived from two parts: 1) Histor

Sponsors

Shenzhen Bao'an District Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age = 18 years old; 2. Meets the diagnostic criteria of "Community-acquired Pneumonia Diagnosis and Treatment Guidelines"; 3. No antibiotic treatment was used within 14 days prior to enrollment; 4. Patients can have other diseases simultaneously, but no special treatment is required during the treatment period, and it does not affect the primary diagnosis; 5. Clinical Pulmonary Infection Score (CPIS) > 6 points; 6. The patient has given informed consent and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Along with other pulmonary diseases such as pulmonary edema, tuberculosis, pulmonary vascular inflammation, etc.; 2. Suffering from neoplastic diseases; 3. Patients with liver and kidney dysfunction as well as cardiovascular diseases; 4. Patients allergic to the drugs in this study; 5. Special groups such as pregnant or lactating women, minors, and individuals with mental disorders, etc.; 6. Patients with severe pneumonia.

Design outcomes

Primary

MeasureTime frame
Observation of inflammatory indicators;

Secondary

MeasureTime frame
Core Symptom Relief Time;Coagulation function indicators;Observation of symptoms and signs;TCM Syndrome Score;

Countries

China

Contacts

Public ContactXiejiajia

Shenzhen Bao'an District Traditional Chinese Medicine Hospital

xiejiajiabazyy@163.com13823107410

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 7, 2026